Pra Health (PRAH)
Overall PRAH gets a fundamental rating of 2 out of 10. We evaluated PRAH against 58 industry peers in the Life Sciences Tools & Services industry. PRAH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PRAH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PRAH was profitable.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.98% | ||
| ROE | 13.71% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.4% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRAH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PRAH has an Altman-Z score of 3.56. This indicates that PRAH is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.74 indicates that PRAH is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.56 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
PRAH has a Current Ratio of 1.21. This is a normal value and indicates that PRAH is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.21 indicates that PRAH should not have too much problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 |
3. Growth
3.1 Past
PRAH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.36%.
The Earnings Per Share has been growing by 19.06% on average over the past years. This is quite good.
Looking at the last year, PRAH shows a small growth in Revenue. The Revenue has grown by 6.57% in the last year.
Measured over the past years, PRAH shows a quite strong growth in Revenue. The Revenue has been growing by 14.55% on average per year.
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS growth Q2Q28.57%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Revenue growth Q2Q19.15%
3.2 Future
Based on estimates for the next years, PRAH will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.49% on average per year.
Based on estimates for the next years, PRAH will show a quite strong growth in Revenue. The Revenue will grow by 9.45% on average per year.
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 32.65 indicates a quite expensive valuation of PRAH.
PRAH's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.15.
PRAH is valuated rather expensively with a Price/Forward Earnings ratio of 23.77.
PRAH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.20.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.65 | ||
| Fwd PE | 23.77 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.96 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PRAH's earnings are expected to grow with 16.62% in the coming years.
PEG (NY)1.12
PEG (5Y)1.71
EPS Next 2Y20.83%
EPS Next 3Y16.62%
5. Dividend
5.1 Amount
No dividends for PRAH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Pra Health
NASDAQ:PRAH (6/30/2021, 7:12:54 PM)
After market: 166.01 +0.8 (+0.48%)165.21
-2.8 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.70B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.65 | ||
| Fwd PE | 23.77 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.12
PEG (5Y)1.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.98% | ||
| ROE | 13.71% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 10.03% | ||
| PM (TTM) | 6.4% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y
EPS growth Q2Q
EPS Next Y29.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y